Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -67.40% is in line with its 1-year average of -61.56%, around the middle of its 1-year range (-80.55%–-50.29%).
As of the fiscal period ended Friday, July 31, 2026. 7.34% below its 12-month average of -62.79%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2027 (2026-07-31): -67.40%.
RETURN ON EQUITY (ROE)
-67.40%
RETURN ON EQUITY (ROE) AVG TTM
-62.79%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-7.34%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-60.44%
vs the sector median at left
Kestra Medical Technologies, Ltd.
Market Cap
$1.59B
Return on Equity (ROE)
-67.40%
TTM Avg
-62.79%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.60B
Return on Equity (ROE)
-77.83%
TTM Avg
1723.94%
3Y Avg
818.18%
5Y Avg
546.13%
Market Cap
$1.57B
Return on Equity (ROE)
-60.17%
TTM Avg
-20.40%
3Y Avg
-40.27%
5Y Avg
-36.46%
Market Cap
$1.61B
Return on Equity (ROE)
-57.97%
TTM Avg
-51.00%
3Y Avg
-97.84%
5Y Avg
-100.56%
Market Cap
$1.61B
Return on Equity (ROE)
-6.27%
TTM Avg
-14.95%
3Y Avg
-10.20%
5Y Avg
-10.20%
Market Cap
$1.61B
Return on Equity (ROE)
3.03%
TTM Avg
0.59%
3Y Avg
-0.01%
5Y Avg
1.68%
Market Cap
$1.62B
Return on Equity (ROE)
N/A
TTM Avg
-1058.20%
3Y Avg
-465.87%
5Y Avg
-348.95%
Market Cap
$1.63B
Return on Equity (ROE)
17.72%
TTM Avg
5.08%
3Y Avg
0.03%
5Y Avg
-3.88%
Market Cap
$1.54B
Return on Equity (ROE)
-1462.12%
TTM Avg
-276.13%
3Y Avg
-155.50%
5Y Avg
-107.48%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kestra Medical Technologies, Ltd. (KMTS) | $1.59B | -67.40% | -62.79% | N/A | N/A |
| uniQure N.V. (QURE)vs › | $1.60B | -77.83% | 1723.94% | 818.18% | 546.13% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | -60.17% | -20.40% | -40.27% | -36.46% |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.61B | -57.97% | -51.00% | -97.84% | -100.56% |
| Septerna Inc (SEPN)vs › | $1.61B | -6.27% | -14.95% | -10.20% | -10.20% |
| Omnicell, Inc. (OMCL)vs › | $1.61B | 3.03% | 0.59% | -0.01% | 1.68% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.62B | N/A | -1058.20% | -465.87% | -348.95% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.63B | 17.72% | 5.08% | 0.03% | -3.88% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | -1462.12% | -276.13% | -155.50% | -107.48% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 28.97% | 13.25% | 22.73% | 32.77% |
ROE
-67.4%
ROA
-43.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-07-31 | -67.40% |
| 2026-04-30 | -50.69% |
| 2026-01-31 | -50.29% |
| 2025-10-31 | -80.55% |
| 2025-07-31 | -65.03% |
| 2025-04-30 | -55.41% |
